Urimax Capsules (Tamsulosin Hydrochloride)

Composition

URIMAX-0.2 Capsules
Each capsule contains:
Tamsulosin Hydrochloride .... 200 mcg
(as modified-release pellets)

URIMAX-0.4 Capsules
Each capsule contains:
Tamsulosin Hydrochloride .... 400 mcg
(as modified-release pellets)
Dosage Form

Capsule
Pharmacology
Pharmacodynamics

Mechanism of Action
The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in the prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck leading to constriction of the bladder outlet. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha1-adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra and bladder neck. Blockade of these adrenoceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in the symptoms of BPH.

Tamsulosin hydrochloride, an alpha1-adrenoreceptor blocking agent, exhibits selectivity for alpha1-receptors in the human prostate. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha1A, alpha1B and alpha1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in the human prostate are of the alpha 1A subtype.

Tamsulosin hydrochloride capsules are not intended for use as an antihypertensive drug.
Storage and Handling Instructions

Store in a cool dry place.
Packaging Information

URIMAX-0.2: Blister pack of 10 capsules
URIMAX-0.4: Blister pack of 15 capsules